Clinton Snow
Directeur/Membre du Conseil chez ICETANA LIMITED
Postes actifs de Clinton Snow
Sociétés | Poste | Début | Fin |
---|---|---|---|
ICETANA LIMITED | Directeur/Membre du Conseil | 08/02/2022 | - |
DIMERIX LIMITED | Directeur/Membre du Conseil | 01/05/2023 | - |
PolyActiva Pty Ltd.
PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Clinton Snow
Formation de Clinton Snow
University of Melbourne | Undergraduate Degree |
Statistiques
Internationale
Australie | 5 |
Opérationnelle
Director/Board Member | 3 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 3 |
Technology Services | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
ICETANA LIMITED | Technology Services |
DIMERIX LIMITED | Health Technology |
Entreprise privées | 1 |
---|---|
PolyActiva Pty Ltd.
PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |
- Bourse
- Insiders
- Clinton Snow
- Expérience